ANGLE plc (AGL) - Product Pipeline Analysis, 2018 Update

Published by Global Data on 27th December 2018 | Ref: 1127992 | This Report Is In Stock

$750 | Single User
$1500 | Site License
$2250 | Enterprise License
$750 | Single User
$1500 | Site License
$2250 | Enterprise License



ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease. Its product Parsortix cell separation system, which captures very rare circulating tumor cells in cancer patient blood. ANGLE’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The company’s cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. It provides liquid biopsy (blood test) that enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The company’s harvested CTCs have a range of applications such as diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring. It has operations in the US and the UK. ANGLE is headquartered in Guildford, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company ANGLE plc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ANGLE plc Company Overview 5

ANGLE plc Company Snapshot 5

ANGLE plc Pipeline Products and Ongoing Clinical Trials Overview 5

ANGLE plc – Pipeline Analysis Overview 8

ANGLE plc - Key Facts 8

ANGLE plc - Major Products and Services 9

ANGLE plc Pipeline Products by Development Stage 10

ANGLE plc Ongoing Clinical Trials by Trial Status 12

ANGLE plc Pipeline Products Overview 14

Parsortix GEN2 14

Parsortix GEN2 Product Overview 14

Parsortix System 15

Parsortix System Product Overview 15

Parsortix-Based Test - Breast Cancer 16

Parsortix-Based Test - Breast Cancer Product Overview 16

Parsortix-Based Test - Colorectal Cancer 17

Parsortix-Based Test - Colorectal Cancer Product Overview 17

Parsortix-Based Test - Head & Neck Cancer 18

Parsortix-Based Test - Head & Neck Cancer Product Overview 18

Parsortix-Based Test - Lung Cancer 19

Parsortix-Based Test - Lung Cancer Product Overview 19

Parsortix-Based Test - Ovarian Cancer Triage 20

Parsortix-Based Test - Ovarian Cancer Triage Product Overview 20

Parsortix-Based Test - Ovarian Cancer Triage Clinical Trial 21

Parsortix-Based Test - Pancreatic Cancer 22

Parsortix-Based Test - Pancreatic Cancer Product Overview 22

Parsortix-Based Test - Prostate Cancer 23

Parsortix-Based Test - Prostate Cancer Product Overview 23

ANGLE plc - Key Competitors 24

ANGLE plc - Key Employees 25

ANGLE plc - Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

ANGLE plc, Recent Developments 27

Jun 04, 2018: ANGLE: Encouraging Progress in ANG-002 FDA Clinical Study 27

May 14, 2018: Angle Appoints Leading NHS Prostate Cancer Surgeon As Scientific Advisor 27

May 03, 2018: Angle and Qiagen Present Poster at Leading Cancer Conference Demonstrating Utility of Angle''s Parsortix System in Conjunction With Qiagen''s Adnatest Assay 28

Apr 19, 2018: Angle''s Parsortix System Showcased In Multiple Presentations At Leading Cancer Conference AACR 2018 28

Apr 19, 2018: Breakthrough Research Demonstrates Parsortix Workflow For Culturing Circulating Tumor Cells For In-Vitro Drug Testing 29

Apr 05, 2018: First Patient Enrolled In Clinical Study To Support FDA Clearance Of The Parsortix System 30

Mar 26, 2018: Angle''S Ovarian Cancer Risk Assessment Achieves The Highest Sensitivity And Specificity For Predicting Cancer 30

Feb 06, 2018: ANGLE: Research Grant From Abbott 31

Jan 31, 2018: ANGLE: Interim Results for the six months ended 31 October 2017 32

Jan 16, 2018: ANGLE: Webinar: Using The Parsortixtm System To Identify Drugs That May Arrest Cancer Metastasis 33

Appendix 34

Methodology 34

About GlobalData 37

Contact Us 37

Disclaimer 37

Additional Details


Global Data

Publisher Information


1127992 | GDME85283PD

Number of Pages


Report Format


This report is published by Global Data

Download Free Report Summary PDF

ANGLE plc (AGL) - Product Pipeline Analysis, 2018 Update [Updated: 27-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types


Buy now using our secure payment system.